I-Mab has released a corporate presentation detailing its progress and strategic initiatives in drug development. Key highlights include the advancement of their bispecific antibodies, givastomig and ragistomig, targeting gastric cancers and refractory/relapsed cancers, respectively. The presentation also outlines the ongoing Phase 1b expansion study for givastomig, which is enrolling ahead of schedule, with topline data expected in the first quarter of 2026. Additionally, I-Mab reports a strong financial position with $168.6 million in cash as of March 31, 2025, projected to support operations through 2027. You can access the full presentation through the link below.